Anthera Pharmaceuticals Inc. (ANTH)

Company Description

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Clinical-stage program includes a Phase 2, blisibimod study. Blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others.

COMPANY ADDRESS
25801 Industrial Blvd.
Suite B
Hayward, CA 94545
United States

COMPANY PHONE
510-856-5600

COMPANY WEBSITE



Get BioInvest's perspective on Anthera's CEO


Latest Company News

Robbins Arroyo LLP: Anthera Pharmaceuticals, Inc. (ANTH) Misled Shareholders ... Yahoo Finance - Feb 17, 2017 Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Anthera Pharmaceuticals, Inc. ("Anthera") (ANTH) in the U.S. District Court for the Northern District of California. The complaint is brought on ... The Anthera Pharmaceuticals Inc. (ANTH) Trading Down 4.1% on Analyst Downgrade - DailyQuint Anthera Pharmaceuticals, Inc. (ANTH): How technical indicators have come out? - Post Analyst [...]
Fri, Feb 17, 2017 8:03:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc. (ANTH) Soars 11.79% on February 15 Equities.com - Feb 15, 2017 Anthera Pharmaceuticals Inc. (ANTH) had a good day on the market for Wednesday February 15 as shares jumped 11.79% to close at $0.71. The Anthera Pharmaceuticals, Inc. (ANTH) Rating Decreased to Sell at the Zacks ... - DailyQuint Trading the Biotech News: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Arena ... - The Voice Registrar [...]
Wed, Feb 15, 2017 10:30:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc. (ANTH) Soars 7.22% on February 10 Equities.com - Feb 10, 2017 Anthera Pharmaceuticals Inc. (ANTH) had a good day on the market for Friday February 10 as shares jumped 7.22% to close at $0.62. [...]
Fri, Feb 10, 2017 10:30:00 PM, Continue reading at the source
Lifshitz & Miller LLP Announces Investigation of Anthera Pharmaceuticals, Inc ... Yahoo Finance - Feb 3, 2017 Lifshitz & Miller announces investigation on behalf of ANTH investors concerning the development of CHABLIS-SC1 and liprotamase after ANTH disclosed both treatments failed to meet primary endpoints. [...]
Fri, Feb 03, 2017 10:03:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc. (ANTH) Soars 5.61% on February 02 Equities.com - Feb 2, 2017 Anthera Pharmaceuticals Inc. (ANTH) had a good day on the market for Thursday February 02 as shares jumped 5.61% to close at $0.58. News review of 2 biotech stocks: Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN ... - The Voice Registrar Analysts Release Average Price Target Of 2.42 On Anthera Pharmaceuticals, Inc ... - UK Market News [...]
Thu, Feb 02, 2017 10:30:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Is A Discount Entry Opportunity Insider Financial - Jan 16, 2017 Anthera Pharmaceuticals Inc (NASDAQ:ANTH) plunged into the close of 2016, and hasn't been able to stage any degree of recovery throughout early 2017. Active Biotech Stock News: Anthera Pharmaceuticals, Inc. (ANTH), BioPharmX ... - The Independent Republic [...]
Mon, Jan 16, 2017 5:44:00 PM, Continue reading at the source
The Anthera Pharmaceuticals, Inc. (ANTH) Cut to Neutral at the Citigroup Inc. DailyQuint - Jan 4, 2017 Citigroup Inc. lowered shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) from a buy rating to a neutral rating in a report released on Thursday morning. Average Price Target Of 2.42 Issued For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard [...]
Wed, Jan 04, 2017 6:56:00 AM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Looks Good For A Recovery Market Exclusive - Dec 28, 2016 Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is heading into the close of the year more than 60% down on its early week market cap, on the release of some seemingly disappointing data from one of its lead studies. Buzz Stocks: QUALCOMM, Inc., Anthera Pharmaceuticals Inc, and Live Ventures Inc - Schaeffers Research (blog) Anthera Pharma (ANTH) Phase 3 SOLUTION Study with Sollpura in CF Narrowly ... - StreetInsider.com [...]
Wed, Dec 28, 2016 1:16:00 PM, Continue reading at the source
Anthera Pharma plunges 66% after missing target in study MarketWatch - Dec 27, 2016 Anthera Pharmaceuticals Inc. ANTH, -2.38% lost roughly two-thirds of its market value in late trading Tuesday after the company announced that one of its drugs had come up short in a study. [...]
Tue, Dec 27, 2016 9:55:00 PM, Continue reading at the source
Anthera Announces Leadership Transition in Preparation of Commercialization of ... GlobeNewswire (press release) - Dec 6, 2016 06, 2016 (GLOBE NEWSWIRE) -- Today the Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Board of Directors announced J. Craig Thompson has been promoted to Chief Executive Officer. [...]
Tue, Dec 06, 2016 9:10:00 PM, Continue reading at the source